Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Studies from Charite University add new findings in the area of cancer vaccines
July 8th, 2008
"Active specific immunization against cancer is a compelling concept which has been under investigatation for several decades. Among tumor vaccine approaches, a modified vaccinia Ankara (MVA) virus vector encoding the oncofetal antigen 5T4 (TroVax (R)) is one of the most advanced," investigators in Berlin, Germany report. "Here, we summarize clinical and immunological data on TroVax in various malignant diseases. The induction of a specific immune response was seen in the majority of patients and across all clinical trials, and preliminary clinical results, particularly in renal cell cancer (RCC), are encouraging," wrote P. Kiewe and colleagues, Charite...
Source: Cancer Weekly (2008-07-08)
|
